Gregg W. Stone MD
@GreggWStone
Interventional cardiologist, trialist, innovator, educator, husband, father, loyal friend
As far as I know, this is the world’s longest-running annual vulnerable plaque and patient meeting. It is extremely high-level. Definitely worth registering and watching virtually.
Registration Now Open: VPM 2025 🗓️ 15–17 September 2025 🌐 Virtual Attendance Only #VPM2025 is a forum where ideas that have shaped the field of ischaemic heart disease have been born. With a world-leading faculty of nearly 80 international pioneers from top institutions, VPM…
Registration Now Open: VPM 2025 🗓️ 15–17 September 2025 🌐 Virtual Attendance Only #VPM2025 is a forum where ideas that have shaped the field of ischaemic heart disease have been born. With a world-leading faculty of nearly 80 international pioneers from top institutions, VPM…
So surprised the answers are all over the place. Holdover effect of the JAMA article >10 yrs ago showing assn of ICU RHC use & death, since debunked, w/many studies showing assn w/RHC use & lower death in shock. But no definitive RCTs. I would use RHC in ~100% of shock cases.
How often do you insert a right heart catheter to manage cardiogenic shock?
How often do you insert a right heart catheter to manage cardiogenic shock?
Our new PROSPECT II study in Circulation comparing untreated non-obstructive lsns in STEMI & NSTEMI. ~4 such lsns per pt. 2-feature high-risk plaques were equally present (in 38.8% vs. 32.7%; P=0.11). 4-yr rates of untreated lesion-related MACE were also similar (8.6% vs 7.8%).
I'm thrilled to announce that we've completed randomizing 1252 pts with LVEF <40% and complex CAD to high-risk PCI with Impella CP support vs. control. Now we are in the 1-year follow-up phase and then the results of the PROTECT IV trial will be reported.
Saddened beyond words. Dimitri was a very special person.
We are deeply saddened by the passing of our esteemed colleague and dear friend, Dr. Dimitri Karmpaliotis. Dimitri was not only a world-class interventionalist, but also a visionary thinker, a generous mentor, and a tireless advocate for better patient care. @CtoEuro
Our publication in EHJ: In ILUMIEN IV, >50% of lesions were mod/sev calcified. OCT-guided PCI in calcified lesions reduced 2-yr rate of TVF and serious MACE - one of the best uses for OCT guidance! Free access link: academic.oup.com/eurheartj/adva…
2nd new PROSPECT II publ, this in JACC Int: hs-CRP (inflammation) was independently associated with both diffuse cor plaque and lipid deposition as well as focal vulnerable plaques. Coupled with the JACC article: LDL & CRP → diffuse plaque and lipid whereas Lp[a] & CRP → VP.
![GreggWStone's tweet image. 2nd new PROSPECT II publ, this in JACC Int: hs-CRP (inflammation) was independently associated with both diffuse cor plaque and lipid deposition as well as focal vulnerable plaques. Coupled with the JACC article: LDL &amp; CRP → diffuse plaque and lipid whereas Lp[a] &amp; CRP → VP.](https://pbs.twimg.com/media/GsCvb1wWQAAmV11.jpg)
![GreggWStone's tweet image. 2nd new PROSPECT II publ, this in JACC Int: hs-CRP (inflammation) was independently associated with both diffuse cor plaque and lipid deposition as well as focal vulnerable plaques. Coupled with the JACC article: LDL &amp; CRP → diffuse plaque and lipid whereas Lp[a] &amp; CRP → VP.](https://pbs.twimg.com/media/GsCvgftWYAAA9-Z.png)
![GreggWStone's tweet image. 2nd new PROSPECT II publ, this in JACC Int: hs-CRP (inflammation) was independently associated with both diffuse cor plaque and lipid deposition as well as focal vulnerable plaques. Coupled with the JACC article: LDL &amp; CRP → diffuse plaque and lipid whereas Lp[a] &amp; CRP → VP.](https://pbs.twimg.com/media/GsCvjYdWsAAoinY.png)
![GreggWStone's tweet image. 2nd new PROSPECT II publ, this in JACC Int: hs-CRP (inflammation) was independently associated with both diffuse cor plaque and lipid deposition as well as focal vulnerable plaques. Coupled with the JACC article: LDL &amp; CRP → diffuse plaque and lipid whereas Lp[a] &amp; CRP → VP.](https://pbs.twimg.com/media/GsCvjYbWgAA41i0.png)
Our JACC publ from PROSPECT II. ↑ TC, LDL-C, & non-HDL-C were strongly associated with pancoronary athero and lipid deposition. ↑ Lp(a) was strongly associated with focal vulnerable plaques→unique role for Lp(a) role in plaque progression & vulnerability -synergistic with LDL.
sciencedirect.com/science/articl…
Could you please share it's link.
Our publ of outcomes of PCI vs. CABG in ISCHEMIA now online in AHJ. Even though this was NOT a randomized comparison, everyone wanted to see it. For the 1203 pts (385 CABG, 818 PCI), the adj 4y primary event rate was 14.5% for CABG & 13.2% for PCI (diff 1.3%, 95%CI -4.9% - 7.7%).
Celebrating my son-in-law’s PhD graduation from Yale - everything on the cake is meaningful. Future of the next generation is bright!
Our publ in EHJ: state of the art review of intrer-atrial shunting - potentially a major breakthrough in HFrEF and selected pts with HFpEF. Add to this the ongoing placebo-procedure controlled ALLAY-HFrEF trial which has just started randomizing 350 HFrEF pts.
Our new publ from COAPT in Circ CV Interv: Elevated natriuretic peptides were a stronger risk factor for death and HF hosp than prior HF hosp within 1 yr, although prognosis was worst if both were present. MitraClip improved outcomes regardless of risk.
RECHARGE is actively randomizing women, Black and Hispanic pts with multivessel or left main CAD in the US and Canada to PCI vs CABG with a novel primary endpoint of improved survival and quality of life. 50/1200 pts enrolled to date. if you would like to participate DM me.
ECLIPSE publ today in Lancet. In 2005 pts with severe lsn calcification by angiography that did not absolutely require atherectomy, there were no sig differences in acute MSA or 1-year TVF with orbital atherectomy vs. balloon pre-dilatation. Free link: authors.elsevier.com/a/1krhgV-4XSfdR
